Evidence map›Paper›PMID 42278253›Full record

ReviewInternational journal of molecular sciences2026

Functional Pathological Features and Molecular Markers in Alzheimer's Disease.

Mee-Na Park, Hae Won Kim, Jeong-Ho Hong, Jin Kyung Kim, Seung-Bo Lee, Hye Suk Baek, Soyoung Kwak, Ye Jin Kwon, Kibeom Park, Jieun Jeon and 4 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mee-Na ParkDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.ORCID 0000-0002-8066-0134
Hae Won KimDepartment of Nuclear Medicine, Keimyung University Dongsan Hospital, 1035 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Jeong-Ho HongDepartment of Neurology, Keimyung University Dongsan Hospital, 1035 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Jin Kyung KimDepartment of Microbiology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Seung-Bo LeeDepartment of Medical Informatics, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Hye Suk BaekDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Soyoung KwakDepartment of Nuclear Medicine, Keimyung University Dongsan Hospital, 1035 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.ORCID 0000-0001-9386-8121
Ye Jin KwonDepartment of Nuclear Medicine, Keimyung University Dongsan Hospital, 1035 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Kibeom ParkDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Jieun JeonDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Na Hyeon HeoDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Seong-Hun LeeDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.ORCID 0009-0001-1002-9523
Juhyeon ChoDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
Shin KimDepartment of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeol-Daero, Dalseo-Gu, Daegu 42601, Republic of Korea.ORCID 0000-0002-1099-5027

Funding

National Research Foundation of Korea RS-2023-00246208National Research Foundation of Korea RS-2023-00249115National Research Foundation of Korea RS-2024-00405401National Research Foundation of Korea RS-2024-00439078National Research Foundation of Korea RS-2025-25430279
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder defined not only by amyloid-β plaques and tau pathology but also by several interacting processes that drive disease progression. These include neuroinflammation, neuronal cell death, synaptic dysfunction, blood-brain barrier (BBB) breakdown, and myelin and axonal damage. Together, they lead to neuronal loss and cognitive decline. In this review, we present a cell-centered framework linking these processes with key molecular markers. Neuroinflammation is driven by activated microglia and astrocytes and is associated with markers such as Iba1, CD68, GFAP, and C3, along with cytokines including IL-1β and TNF-α. Neuronal cell death occurs through apoptosis, ferroptosis, pyroptosis, and necroptosis, with markers such as caspase-3, GPX4, GSDMD, and MLKL. Synaptic dysfunction is reflected by reduced synaptic proteins, including synaptophysin and PSD-95. BBB breakdown increases permeability and reduces clearance of toxic molecules. Myelin and axonal damage, associated with MBP and NfL, disrupt neural connectivity. These processes are dynamically interconnected and may contribute differently across disease stages. This integrated cell-centered and systems-level framework provides insight into AD progression while highlighting potential biomarkers and therapeutic targets for diagnosis, disease monitoring, and therapeutic intervention.

Indexed as

Alzheimer DiseaseAnimalsBiomarkersBlood-Brain BarrierCell DeathHumansNeuroinflammatory DiseasesBiomarkersAlzheimer’s diseasebiomarkersneuroinflammationneuronal cell deathsynaptic dysfunction

Identifiers

PMID42278253
PMCPMC13256995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.